Significance of today's Ann, page-3

First 3 Last

Share
Profile

Follow
Rappa

6,264 Posts.

13/02/17

18:07

Post #: 22577525
Share

Originally posted by The Yankee ↑

Comparing the Aug 09, 2016 Phase 2 RA trial results with today's Ann:
1. The 08/09/2016 trial results were (obviously) in humans but the primary objective of that was to evaluate safety and tolerability of MPC-300-IV.
a) safety was established - meaning no serious adverse affects
b) Tolerability - was well tolerated after intravenous injection of the stem cells
2. The other objective was to measure effectiveness. Which was done by
a) Improvement in ACR 70, ACR 50 and ACR 20 (these are the patients' assessments)
b) Improvements were shown in swollen joint counts, investigator global assessment, patient global assessment, and
patient pain scores.

As we can see, most everything fro the human study was based on improvement in pain and function. There were no objective measurements within the human anatomy/biology itself.

So what about the study on sheep??
Here are the main things to be noted:
a) Its showed objective improvements by way of reduced joint cartilage erosions, and improved synovial inflammation and histopathology
The important thing to note here is that cartilage erosion, synovial inflammation and histopathology were NOT evaluated in the human trial.
b) STRO-1 positive MPCs have been shown to be at least 10- fold more potent inhibitors of T-cell activation and proliferation than conventional plastic-adherent Mesenchymal Stem Cells (MSCs)
c) The study in sheep provides translational and mechanistic support to the trial in humans.

So what the heck does "translational and mechanistic support" mean?
Translational means scientific discoveries are moved along a virtual path from the laboratory into real-world practice, leading to improved human health.
Mecahanistic means that which explains the mechanism of action (in this case, how the stem cells are acting physically to improve the cartilage, synovial fluids, etc.)

My take:
1. Using STRO-1 postive MPCs is 10 times more potent
2. Mesoblast's MPCs for RA is clearly showing measurable improvement in cartilage erosion, synovial inflammation and histopathology - something that wasn't done in the human trial yet
3. The super awesome results in sheep provide support to the human trial in that humans too could show these objective, measurable improvements (though that is something that needs to be demonstrated in humans of course).

Awesome, awesome results!!

Expand

Is there a secret message @Yankee?

I can see red, white and blue in your post!

MSB Price at posting: $1.54 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 7 more messages in this thread...

First 3 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.51		Change 0.020(1.34%)		Mkt cap ! $1.724B

Open	High	Low	Value	Volume
$1.57	$1.58	$1.41	$18.15M	12.09M

Buyers (Bids)

No.	Vol.	Price($)
1	3418	$1.50

Sellers (Offers)

Price($)	Vol.	No.
$1.51	24361	5

View Market Depth

No.	Vol.	Price($)
1	3418	1.500
1	13000	1.495
7	91808	1.490
4	58451	1.485
7	138437	1.480

Price($)	Vol.	No.
1.510	24361	5
1.515	44181	1
1.520	192161	6
1.525	36465	2
1.530	29631	3

Last trade - 16.10pm 07/10/2024 (20 minute delay)

MSB (ASX) Chart

Significance of today's Ann, page-3

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Significance of today's Ann, page-3

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News